Neuralstem Announces Publication of a Study in Nature Medicine Showing Benefits of NSI-566 in a Primate Model of Spinal Cord Injury. Mar 13, 2018. Quarter Ended Sep 30, 2017. American Stock Transfer and Trust Company, LLC. Brooklyn, NY 11219. Dixon Hughes Goodman LLP. 809 Glen Eagles Court. Baltimore, MD 21286. 2018 Neuralstem, Inc.
http://investor.neuralstem.com/
TODAY'S RATING
>1,000,000
Date Range
HIGHEST TRAFFIC ON
Tuesday
LOAD TIME
0.8 seconds
16x16
32x32
PAGES IN
THIS WEBSITE
0
SSL
EXTERNAL LINKS
24
SITE IP
34.235.255.140
LOAD TIME
0.798 sec
SCORE
6.2
Investor Relations :: Neuralstem, Inc. (CUR) | investor.neuralstem.com Reviews
https://investor.neuralstem.com
Neuralstem Announces Publication of a Study in Nature Medicine Showing Benefits of NSI-566 in a Primate Model of Spinal Cord Injury. Mar 13, 2018. Quarter Ended Sep 30, 2017. American Stock Transfer and Trust Company, LLC. Brooklyn, NY 11219. Dixon Hughes Goodman LLP. 809 Glen Eagles Court. Baltimore, MD 21286. 2018 Neuralstem, Inc.
Major Depression
http://www.neuralstem.com/pharmaceuticals-for-depression
Sign up for Breaking News Email Alerts. For Major Depressive Disorder. NSI-189 Phase Ia and Ib trials completed. Multi-center Phase II first patient enrollment expected in 1Q 2016. Most current major depressive disorder (MDD) treatments are oral medications that modulate levels of different neurotransmitters in the brain. One class, selective serotonin reuptake inhibitors (SSRIs), is commonly believed to be the most widely-prescribed type of antidepressants in the world. For more information on the trial:.
Ischemic Stroke
http://www.neuralstem.com/cell-therapy-for-ischemic-stroke
Sign up for Breaking News Email Alerts. NSI-566 Phase I / II trial commenced in December 2013, in collaboration with BaYi Brain Hospital in Beijing. Phase II commencement expected in 2016. Rebuilding neural circuitry lost to ischemic damage and production of factors that promote repair and recovery of surviving tissue. Direct stereotactic injections into the brain. Neuralstem China Phase I/II Ischemic Stroke Trial. The Phase I / II ischemic stroke trial, which commenced in December 2013, is testing direc...
ALS
http://www.neuralstem.com/cell-therapy-for-als
Sign up for Breaking News Email Alerts. Neuralstem Cell Therapy for ALS. FDA-approved multi-center Phase II NSI-566/ALS clinical trial, with significant increase in dosing, concluded in 1Q15. Larger, controlled, registration directed NSI-566/ALS clinical trial expected to commence in 2016. Direct injections into the spinal cord. In humans, Neuralstem expects that the transplanted cells will:. GRAFT permanently into the region where they were transplanted. REBUILD circuitry with the patient motor neurons.
Chronic Spinal Injury
http://www.neuralstem.com/cell-therapy-for-sci
Sign up for Breaking News Email Alerts. For Spinal Cord Injury. FDA-approved NSI-566/cSCI Phase I Safety Clinical Trial completed the last surgery in July 2015, with six-month post-observation period; FDA amended protocol to four patients total. NSI-566/Acute SCI Phase I/II trial awaiting IND approval. Rebuilding neural circuitry across and below the injury site. Direct injections into the spinal cord in and around the injury site. Nerve cell death within the spinal cord. Disruption of nerve pathways.
Repairing and replacing damaged cells…
http://www.neuralstem.com/cell-therapy
Sign up for Breaking News Email Alerts. Repairing and Replacing Damaged Cells. Patented technology enables isolation. And expansion of human neural stem cells. Regionally specific cells are specialized, already suited to the task. Cells integrate with, and protect, the patient's spinal cord neurons. Cells believed to create new circuitry and express neuroprotective growth factors. There are two primary ways that these cells can provide therapeutic effects. We believe that Neuralstem's cells do both.
About Neuralstem
http://www.neuralstem.com/about-neuralstem
Sign up for Breaking News Email Alerts. Neuralstem's patented technology enables the commercial-scale production of multiple types of central nervous system stem cells, which are under development for the potential treatment of central nervous system diseases and conditions. Neuralstem, Inc. 2016. Cognitive complication due to Diabetes. Website by inktank LLC.
Creating a new class of neuroregenerative drugs…
http://www.neuralstem.com/pharmaceuticals
Sign up for Breaking News Email Alerts. Creating a New Class of Neurogenic Drugs. Unlimited numbers of cells for screening. Four patented first-in-class compounds. World's only human hippocampus neural stem cell lines. An entirely new approach to treating diseases. Using the Brain to Repair Itself. Assaults on neurons in the human hippocampus are now suspected to be linked to many devastating diseases of the mind and brain. Drugs that stimu. Late the generation of new neurons - an aspect of the healthy b...
Cell therapy and drug treatments in development
http://www.neuralstem.com/patient-info-treatments-in-development
Sign up for Breaking News Email Alerts. FDA-approved multi-center dose-escalation Phase II NSI-566/ALS clinical trial primarily evaluating safety concluded in 1Q15. Larger, controlled, registration directed NSI-566/ALS clinical trial expected to commence in 2016. More. NSI-566 Phase I / II trial for ischemic stroke commenced in December 2013, in collaboration with BaYi Brain Hospital in Beijing. Phase II controlled proof-of-concept study commencement expected in 2016. More. Preclinical phase with NSI-566...
TOTAL LINKS TO THIS WEBSITE
24
INVESTOR MALAYSIA
IPO Launch: ABC Corp. December 12, 2011. The ABC corp launch date. December 8, 2011. Dont wait for you. Thank you for attending. December 8, 2011. Attending is a must for everyone here. December 8, 2011. Quarterly Earning Result Announcement: UIO Corp. December 8, 2011. The Malaysian Financial Grapevine. Proudly powered by WordPress.
INVESTOR NIERUCHOMOŚCI Opole, Warszawa, Wrocław, Brzeg, Kluczbork, Namysłów, Żory - Biuro nieruchomości INVESTOR
Ta strona używa plików cookies. Kontynuując przeglądanie naszej strony wyrażasz zgodę na wykorzystywanie przez nas plików cookies. Więcej informacji tutaj. I Oddział w Opolu. Ul Henryka Sienkiewicza 1. Vis a vis G.H. Solaris). Pon - pt. 9.00 - 17.00. Tel 77 400 01 76. II Oddział w Opolu. Ul Gen. Sosnkowskiego 6. Pon - pt. 9.00 - 17.00. Tel 77 453 70 53. III Oddział w Opolu. Pon - pt. 9.00 - 17.00. Tel 77 466 81 24. Pon - pt. 9.00 - 17.00. Tel 22 400 50 56. Ul Mikołaja Reja 15. Tel 77 444 33 44.
MiroHost - Крупнейший хостинг-провайдер в Украине
Крупнейший хостинг-провайдер в Украине.
NETGEAR, Inc. - Investor Relations
Skip to main content. Pricing delayed by 20 minutes. March 29, 2018. Stock Quote and Chart. About NETGEAR, Inc. Or by calling (408) 907-8000. Connect with NETGEAR at http:/ twitter.com/NETGEAR. And http:/ www.facebook.com/NETGEAR. Enter the code shown above. Email Alert Sign Up Confirmation. Louisville, KY 40233. Powered By Q4 Inc. Opens in new window).
Netia SA - Netia SA
This website uses cookie files (small text files stored by the internet browser on the user’s device) for such purposes as: statistical analysis of traffic, adjustment of the website appearance and content to the individual needs of the user etc. By enabling cookies in your browser you give your consent for their use. If you do not agree for using cookies change the preferences of your browser. Find out more in the Privacy Policy. Wybierz usługi odpowiadające różnym potrzebom firm. Convenience translatio...
Investor Relations :: Neuralstem, Inc. (CUR)
Neuralstem Announces Publication of a Study in Nature Medicine Showing Benefits of NSI-566 in a Primate Model of Spinal Cord Injury. Mar 13, 2018. Quarter Ended Sep 30, 2017. American Stock Transfer and Trust Company, LLC. Brooklyn, NY 11219. Dixon Hughes Goodman LLP. 809 Glen Eagles Court. Baltimore, MD 21286. 2018 Neuralstem, Inc.
Neuromama, Ltd. (NERO)
NEUROMAMA, LTD. IS THE FAST GROWTH COMPANY TODAY . AND . THE BLUEST OF THE BLUES . A REAL ASSET PLAY OF TOMORROW! Http:/ investor.neuromama.com/due-diligence.html. Today NeuroMama, Ltd. is a very small company in a very large $8 trillion dollar per year Telecommunication, Internet, Entertainment, Hospitality and Media Industries. NeuroMama's real treasure. http:/ investor.neuromama.com/ocean-view-property-in-baja-california.html. NeuroMama has an inventory $100's of billions in Online Advertising. 2) Pre...
Investor Relations - NeuroMetrix, Inc.
Quell Wearable Pain Relief. Annual Reports and Proxies. Annual Reports and Proxies. NeuroMetrix is an innovative health-care company that develops wearable medical technology and point-of-care test that help patients and physicians better manage chronic pain, nerve diseases, and sleep disorders. NeuroMetrix has two principal product lines:. Wearable neuro-stimulation therapeutic devices. Point-of-care neuropathy diagnostic test. Aug 13, 2015. Aug 10, 2015. View all press releases ».
neworiental > For Investors > Investor Relations
New Oriental Announces Results for the Fourth Fiscal Quarter and Fiscal Year Ended May 31, 2015 and Declares a Special Cash Dividend. New Oriental to Report Fourth Quarter and Fiscal Year 2015 Financial Results on July 21, 2015. New Oriental Announces Chief Financial Officer Appointment. New Oriental Announces Results for the Third Fiscal Quarter Ended February 28, 2015. Sign up to receive e-mail alerts whenever New Oriental Education and Technology Group Inc. posts new information to the site. J...Minim...
Newport Corporation | Investor Information
08/26/15 8:00 am CT. Newport Corporation at Jefferies Semiconductors, Hardware and Communications Infrastructure Summit. Ritz Carlton Hotel, Chicago Illinois. Enter your e-mail address . Newport Corporation To Present At Fourth Annual Needham Advanced Industrial Technologies Conference. Newport Corporation Reports Second Quarter And First Half 2015 Results. Newport Corporation To Announce Second Quarter Results On August 4, 2015. Newport Corporation Updates Outlook For The Second Quarter Of 2015.
Investor Relations - NewStar Financial, Inc.
Dec 21, 2017. NewStar Stockholders Approve Acquisition by First Eagle. Nov 20, 2017. NewStar Announces Completion of "Go Shop" Process. View all press releases. Aug 2, 2017 at 10:00 AM ET. NewStar Financial Q2 2017 Earnings Call. May 3, 2017 at 10:00 AM ET. NewStar Financial Q1 2017 Earnings Call. View all events and presentations. Latest Annual Report and Fact Sheet.
SOCIAL ENGAGEMENT